Cardiovascular overexpression of transforming growth factor-β1 causes abnormal yolk sac vasculogenesis and early embryonic death

Circulation Research

Volumn 86, Issue 10, 2000, Pages 1024-1030

  Agah, Ramtin ^a,b   Prasad, K S Srinivasa ^c   Linnemann, Ruth ^a   Firpo, Meri T ^b   Quertermous, Thomas ^c   Dichek, David A ^a,b  

^a GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood vessels; Hematopoiesis; Morphogenesis; Transgenic mice

Indexed keywords

BETA GALACTOSIDASE; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; EMBRYO; EMBRYO DEATH; GENE EXPRESSION; GENE OVEREXPRESSION; GENOTYPE; GROWTH RETARDATION; HEMATOPOIESIS; MORPHOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SMOOTH MUSCLE FIBER; TRANSGENE; TRANSGENIC MOUSE; VASCULAR DISEASE; YOLK SAC;

EID: 0343674521     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.86.10.1024     Document Type: Article

References (45)

1. Akhurst RJ, Lehnen SA, Faissner A, Duffie E. TGF-β in murine morphogenetic processes: the early embryo and cardiogenesis. Development. 1990;108:645-656.
2. Wilcox JN, Derynck R. Developmental expression of transforming growth factors α and β in mouse fetus. Mol Cell Biol. 1988;8:3415-3422.
3. 1 during repair of arterial injury. J Clin Invest. 1991;88:904-910.
4. 1 induces angiogenesis in vivo with a threshold pattern. Lab Invest. 1996;74:600-608.
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
6. 1 is increased in human vascular restenosis lesions. J Clin Invest. 1992;90:1582-1592.
7. 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993;90:10759-10763.
8. 1 suppress intimai hyperplasia in a rat model. J Clin Invest. 1994;93:1172-1178.
9. 1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci U S A. 1998; 95:6983-6988.
10. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655-1658.
11. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994;370:460-462.
12. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med. 1995;1:74-79.
13. Smith JD, Bryant SR, Couper LL, Vary CPH, Gotwals PJ, Koteliansky VE, Lindner V. Soluble transforming growth factor-β type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res. 1999;84: 1212-1222.
14. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development. 1995;121:1845-1854.
15. 1 gene results in multifocal inflammatory disease. Nature. 1992;359:693-699.
16. 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993;90:770-774.
17. Li L, Miano JM, Mercer B, Olson EN. Expression of the SM22α promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells. J Cell Biol. 1996;132:849-859.
18. Moessler H, Mericskay M, Li Z, Nagl S, Paulin D, Small JV. The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Development. 1996;122: 2415-2425.
19. 1 (Ser223, 225). EMBO J. 1992;11:1599-1605.
20. Hogan B, Beddington R, Costantini F, Lacy E. Manipulating the Mouse Embryo: A Laboratory Manual. Plainview, NY: Cold Spring Harbor Laboratory Press; 1994.
21. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
22. Innis MA, Gelfand DH, Sninsky JJ, White TJ. PCR Protocols: A Guide to Methods and Applications. San Diego, Calif: Academic Press; 1990.
23. 1 responsiveness in endothelium in vivo. J Biol Chem. 1996;271:29969-29977.
24. 1: histochemical localization with antibodies to different epitopes. J Cell Biol. 1989;108:653-660.
25. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res. 1993;73:797-807.
26. Humeau L, Chabannon C, Firpo MT, Mannoni P, Bagnis C, Roncarolo M-G, Namikawa R. Successful reconstitution of human hematopoiesis in the SCID-hu mouse by genetically modified, highly enriched progenitors isolated from fetal liver. Blood. 1997;90:3496-3506.
27. MacLellan WR, Brand T, Schneider MD. Transforming growth factor-β in cardiac ontogeny and adaptation. Circ Res. 1993;73:783-791.
28. Copp AJ. Death before birth: clues from gene knockouts and mutations. Trends Genet. 1995;11:87-93.
29. Tsai F-Y, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M, Alt FW, Orkin SH. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature. 1994;371:221-226.
30. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature. 1996;384:66-68.
31. Huang Z-F, Higuchi D, Lasky N, Broze GJ Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood. 1997;90:944-951.
32. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
33. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439.
34. Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, Orkin SH. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J. 1997;16:4374-4383.
35. Lehnen SA, Akhurst RJ. Embryonic expression pattern of TGF-β type-1 RNA suggests both paracrine and autocrine mechanisms of action. Development. 1988;104:263-273.
36. Oshima M, Oshima H, Taketo MM. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol. 1996;179:297-302.
37. Heine UI, Munoz EF, Flanders KC, Ellingsworth LR, Lam H-YP, Thompson NL, Roberts AB, Sporn MB. Role of transforming growth factor-β in the development of the mouse embryo. J Cell Biol. 1987;105:2861-2876.
38. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP. Defective angiogenesis in mice lacking endoglin. Science. 1999;284:1534-1537.
39. Zhao Y, Young SL. Expression of transforming growth factor-β type II receptor in rat lung is regulated during development. Am J Physiol. 1995;269:L419-L426.
40. 1 chimeric gene. Dev Biol. 1996; 175:227-238.
41. 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A. 1995;92:2572-2576.
42. 1. Am J Pathol. 1995;147:42-52.
43. 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J. 1993;12: 1835-1845.
44. Madsen CS, Regan CP, Hungerford JE, White SL, Manabe I, Owens GK. Smooth muscle-specific expression of the smooth muscle myosin heavy chain gene in transgenic mice requires 5′-flanking and first intronic DNA sequence. Circ Res. 1998;82:908-917.
45. Fishman GI. Timing is everything in life: conditional transgene expression in the cardiovascular system. Circ Res. 1998;82:837-844.